William Blair Has Bullish Outlook for BRNS FY2024 Earnings

Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) - Equities research analysts at William Blair increased their FY2024 EPS estimates for Barinthus Biotherapeutics in a note issued to investors on Wednesday, November 6th. William Blair analyst A. Hsieh now anticipates that the company will post earnings per share of ($1.44) for the year, up from their previous estimate of ($1.59). The consensus estimate for Barinthus Biotherapeutics' current full-year earnings is ($1.63) per share. William Blair also issued estimates for Barinthus Biotherapeutics' Q4 2024 earnings at ($0.40) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.52) EPS and FY2026 earnings at ($1.70) EPS.

BRNS has been the topic of a number of other reports. Alliance Global Partners decreased their price objective on Barinthus Biotherapeutics from $11.00 to $9.50 and set a "buy" rating on the stock in a report on Tuesday, August 13th. HC Wainwright reiterated a "buy" rating and set a $5.00 price target on shares of Barinthus Biotherapeutics in a research note on Friday.

Barinthus Biotherapeutics Stock Performance

BRNS traded up $0.02 during mid-day trading on Monday, reaching $1.37. The stock had a trading volume of 6,516 shares, compared to its average volume of 23,606. The stock has a market capitalization of $55.11 million, a P/E ratio of -0.91 and a beta of -0.59. The firm's fifty day simple moving average is $1.29 and its two-hundred day simple moving average is $1.56. Barinthus Biotherapeutics has a 52 week low of $1.11 and a 52 week high of $4.16.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.23. The firm had revenue of $14.97 million for the quarter. During the same quarter in the previous year, the firm earned ($0.37) earnings per share.

Hedge Funds Weigh In On Barinthus Biotherapeutics

Several large investors have recently made changes to their positions in BRNS. M&G Plc bought a new position in Barinthus Biotherapeutics in the second quarter worth approximately $7,276,000. Alphabet Inc. purchased a new stake in Barinthus Biotherapeutics during the 2nd quarter worth approximately $2,119,000. DC Funds LP acquired a new stake in shares of Barinthus Biotherapeutics during the 1st quarter worth approximately $1,528,000. BlueCrest Capital Management Ltd acquired a new stake in shares of Barinthus Biotherapeutics during the 1st quarter worth about $1,292,000. Finally, Ipswich Investment Management Co. Inc. purchased a new position in shares of Barinthus Biotherapeutics during the 2nd quarter worth approximately $32,000. 25.20% of the stock is currently owned by hedge funds and other institutional investors.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.